Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.

Jinsmaa Y, Sharabi Y, Sullivan P, Isonaka R, Goldstein DS.

J Pharmacol Exp Ther. 2018 Jul;366(1):113-124. doi: 10.1124/jpet.118.248492. Epub 2018 Apr 26.

2.

Spectrum of abnormalities of sympathetic tyrosine hydroxylase and alpha-synuclein in chronic autonomic failure.

Isonaka R, Sullivan P, Jinsmaa Y, Corrales A, Goldstein DS.

Clin Auton Res. 2018 Apr;28(2):223-230. doi: 10.1007/s10286-017-0495-6. Epub 2018 Feb 2.

PMID:
29396794
3.

N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.

Goldstein DS, Jinsmaa Y, Sullivan P, Sharabi Y.

Neurochem Res. 2017 Nov;42(11):3289-3295. doi: 10.1007/s11064-017-2371-0. Epub 2017 Aug 24.

PMID:
28840582
4.

Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.

Goldstein DS, Holmes C, Sullivan P, Jinsmaa Y, Kopin IJ, Sharabi Y.

Parkinsonism Relat Disord. 2016 Oct;31:79-86. doi: 10.1016/j.parkreldis.2016.07.009. Epub 2016 Jul 20.

5.

3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.

Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y.

Neurochem Res. 2016 Sep;41(9):2173-8. doi: 10.1007/s11064-016-1959-0. Epub 2016 May 25.

6.

DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells.

Jinsmaa Y, Sullivan P, Sharabi Y, Goldstein DS.

Auton Neurosci. 2016 Jan;194:46-51. doi: 10.1016/j.autneu.2015.12.008. Epub 2015 Dec 31.

7.

Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.

Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y.

J Pharmacol Exp Ther. 2016 Feb;356(2):483-92. doi: 10.1124/jpet.115.230201. Epub 2015 Nov 16.

8.

Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.

Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Kopin IJ, Sharabi Y.

J Neurochem. 2015 Apr;133(1):14-25. doi: 10.1111/jnc.13042. Epub 2015 Feb 25.

9.

The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.

Jinsmaa Y, Cooney A, Sullivan P, Sharabi Y, Goldstein DS.

Neurosci Lett. 2015 Mar 17;590:134-7. doi: 10.1016/j.neulet.2015.01.064. Epub 2015 Jan 28.

10.

Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.

Casida JE, Ford B, Jinsmaa Y, Sullivan P, Cooney A, Goldstein DS.

Chem Res Toxicol. 2014 Aug 18;27(8):1359-61. doi: 10.1021/tx5002223. Epub 2014 Jul 24.

11.

Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein.

Jinsmaa Y, Sullivan P, Gross D, Cooney A, Sharabi Y, Goldstein DS.

Neurosci Lett. 2014 May 21;569:27-32. doi: 10.1016/j.neulet.2014.03.016. Epub 2014 Mar 23.

12.

Cellular localization of dieldrin and structure-activity relationship of dieldrin analogues in dopaminergic cells.

Allen EM, Florang VR, Davenport LL, Jinsmaa Y, Doorn JA.

Chem Res Toxicol. 2013 Jul 15;26(7):1043-54. doi: 10.1021/tx300458b. Epub 2013 Jun 27.

13.

Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Goldstein DS, Sullivan P, Cooney A, Jinsmaa Y, Sullivan R, Gross DJ, Holmes C, Kopin IJ, Sharabi Y.

J Neurochem. 2012 Dec;123(6):932-43. doi: 10.1111/j.1471-4159.2012.07924.x. Epub 2012 Oct 25.

14.

Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease.

Jinsmaa Y, Florang VR, Rees JN, Mexas LM, Eckert LL, Allen EM, Anderson DG, Doorn JA.

Chem Biol Interact. 2011 Jun 30;192(1-2):118-21. doi: 10.1016/j.cbi.2011.01.006. Epub 2011 Jan 13.

15.

Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice.

Marczak ED, Jinsmaa Y, Myers PH, Blankenship T, Wilson R, Balboni G, Salvadori S, Lazarus LH.

Eur J Pharmacol. 2009 Aug 15;616(1-3):115-21. doi: 10.1016/j.ejphar.2009.06.041. Epub 2009 Jul 1.

16.

Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.

Jinsmaa Y, Florang VR, Rees JN, Anderson DG, Strack S, Doorn JA.

Chem Res Toxicol. 2009 May;22(5):835-41. doi: 10.1021/tx800405v.

17.

Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph.

Jinsmaa Y, Marczak ED, Balboni G, Salvadori S, Lazarus LH.

Pharmacol Biochem Behav. 2008 Oct;90(4):651-7. doi: 10.1016/j.pbb.2008.05.008.

18.

Synthesis of opioidmimetics, 3-[H-Dmt-NH(CH(2))(m)]-6-[H-Dmt-NH(CH(2))(n)]-2(1H)-pyrazinones, and studies on structure-activity relationships.

Shiotani K, Miyazaki A, Li T, Tsuda Y, Yokoi T, Ambo A, Sasaki Y, Bryant SD, Jinsmaa Y, Lazarus LH, Okada Y.

Med Chem. 2007 Nov;3(6):583-98.

PMID:
18045209
19.

A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Salvadori S, Trapella C, Fiorini S, Negri L, Lattanzi R, Bryant SD, Jinsmaa Y, Lazarus LH, Balboni G.

Bioorg Med Chem. 2007 Nov 15;15(22):6876-81. Epub 2007 Aug 29.

20.

[N-allyl-Dmt1]-endomorphins are micro-opioid receptor antagonists lacking inverse agonist properties.

Marczak ED, Jinsmaa Y, Li T, Bryant SD, Tsuda Y, Okada Y, Lazarus LH.

J Pharmacol Exp Ther. 2007 Oct;323(1):374-80. Epub 2007 Jul 12.

PMID:
17626793
21.

Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.

Li T, Shiotani K, Miyazaki A, Tsuda Y, Ambo A, Sasaki Y, Jinsmaa Y, Marczak E, Bryant SD, Lazarus LH, Okada Y.

J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.

22.

Further studies on the effect of lysine at the C-terminus of the Dmt-Tic opioid pharmacophore.

Balboni G, Onnis V, Congiu C, Zotti M, Sasaki Y, Ambo A, Bryant SD, Jinsmaa Y, Lazarus LH, Lazzari I, Trapella C, Salvadori S.

Bioorg Med Chem. 2007 May 1;15(9):3143-51. Epub 2007 Feb 22.

23.

Transformation of mu-opioid receptor agonists into biologically potent mu-opioid receptor antagonists.

Li T, Jinsmaa Y, Nedachi M, Miyazaki A, Tsuda Y, Ambo A, Sasaki Y, Bryant SD, Marczak E, Li Q, Swartzwelder HS, Lazarus LH, Okada Y.

Bioorg Med Chem. 2007 Feb 1;15(3):1237-51. Epub 2006 Nov 14.

PMID:
17142049
24.

Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.

Balboni G, Onnis V, Congiu C, Zotti M, Sasaki Y, Ambo A, Bryant SD, Jinsmaa Y, Lazarus LH, Trapella C, Salvadori S.

J Med Chem. 2006 Sep 7;49(18):5610-7.

25.

New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.

Ballet S, Salvadori S, Trapella C, Bryant SD, Jinsmaa Y, Lazarus LH, Negri L, Giannini E, Lattanzi R, Tourwé D, Balboni G.

J Med Chem. 2006 Jun 29;49(13):3990-3.

26.

Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt1]endomorphin-1.

Jinsmaa Y, Marczak E, Fujita Y, Shiotani K, Miyazaki A, Li T, Tsuda Y, Ambo A, Sasaki Y, Bryant SD, Okada Y, Lazarus LH.

Pharmacol Biochem Behav. 2006 Jun;84(2):252-8. Epub 2006 Jun 19.

PMID:
16782179
27.

6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides.

Vázquez ME, Blanco JB, Salvadori S, Trapella C, Argazzi R, Bryant SD, Jinsmaa Y, Lazarus LH, Negri L, Giannini E, Lattanzi R, Colucci M, Balboni G.

J Med Chem. 2006 Jun 15;49(12):3653-8.

28.

Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1).

Balboni G, Guerrini R, Salvadori S, Negri L, Giannini E, Bryant SD, Jinsmaa Y, Lazarus LH.

J Med Chem. 2005 Dec 29;48(26):8112-4.

29.

Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.

Li T, Fujita Y, Shiotani K, Miyazaki A, Tsuda Y, Ambo A, Sasaki Y, Jinsmaa Y, Marczak E, Bryant SD, Salvadori S, Lazarus LH, Okada Y.

J Med Chem. 2005 Dec 15;48(25):8035-44.

PMID:
16335927
30.

New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif.

Li T, Shiotani K, Miyazaki A, Fujita Y, Tsuda Y, Ambo A, Sasaki Y, Jinsmaa Y, Marczak E, Bryant SD, Lazarus LH, Okada Y.

Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. Epub 2005 Sep 23.

PMID:
16183273
31.

From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.

Balboni G, Cocco MT, Salvadori S, Romagnoli R, Sasaki Y, Okada Y, Bryant SD, Jinsmaa Y, Lazarus LH.

J Med Chem. 2005 Aug 25;48(17):5608-11.

PMID:
16107162
32.

Differentiation of opioid receptor preference by [Dmt1]endomorphin-2-mediated antinociception in the mouse.

Jinsmaa Y, Fujita Y, Shiotani K, Miyazaki A, Li T, Tsuda Y, Okada Y, Ambo A, Sasaki Y, Bryant SD, Lazarus LH.

Eur J Pharmacol. 2005 Feb 10;509(1):37-42. Epub 2005 Jan 22.

PMID:
15713427
33.

Studies on the structure-activity relationship of 2',6'-dimethyl-l-tyrosine (Dmt) derivatives: bioactivity profile of H-Dmt-NH-CH(3).

Fujita Y, Tsuda Y, Motoyama T, Li T, Miyazaki A, Yokoi T, Sasaki Y, Ambo A, Niizuma H, Jinsmaa Y, Bryant SD, Lazarus LH, Okada Y.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):599-602.

PMID:
15664820
34.

Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2.

Li T, Fujita Y, Tsuda Y, Miyazaki A, Ambo A, Sasaki Y, Jinsmaa Y, Bryant SD, Lazarus LH, Okada Y.

J Med Chem. 2005 Jan 27;48(2):586-92.

PMID:
15658871
35.

Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic.

Balboni G, Salvadori S, Dal Piaz A, Bortolotti F, Argazzi R, Negri L, Lattanzi R, Bryant SD, Jinsmaa Y, Lazarus LH.

J Med Chem. 2004 Dec 16;47(26):6541-6.

PMID:
15588089
36.

Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.

Balboni G, Salvadori S, Guerrini R, Negri L, Giannini E, Bryant SD, Jinsmaa Y, Lazarus LH.

J Med Chem. 2004 Jul 29;47(16):4066-71.

PMID:
15267245
37.

Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.

Fujita Y, Tsuda Y, Li T, Motoyama T, Takahashi M, Shimizu Y, Yokoi T, Sasaki Y, Ambo A, Kita A, Jinsmaa Y, Bryant SD, Lazarus LH, Okada Y.

J Med Chem. 2004 Jul 1;47(14):3591-9.

PMID:
15214786
38.

Oral bioavailability of a new class of micro-opioid receptor agonists containing 3,6-bis[Dmt-NH(CH(2))(n)]-2(1H)-pyrazinone with central-mediated analgesia.

Jinsmaa Y, Miyazaki A, Fujita Y, Li T, Fujisawa Y, Shiotani K, Tsuda Y, Yokoi T, Ambo A, Sasaki Y, Bryant SD, Lazarus LH, Okada Y.

J Med Chem. 2004 May 6;47(10):2599-610.

PMID:
15115401
39.

Neurite outgrowth-stimulating activities of beta-casomorphins in Neuro-2a mouse neuroblastoma cells.

Sakaguchi M, Murayama K, Jinsmaa Y, Yoshikawa M, Matsumura E.

Biosci Biotechnol Biochem. 2003 Dec;67(12):2541-7.

40.

Novel 2',6'-dimethyl-L-tyrosine-containing pyrazinone opioid mimetic mu-agonists with potent antinociceptive activity in mice.

Jinsmaa Y, Okada Y, Tsuda Y, Shiotani K, Sasaki Y, Ambo A, Bryant SD, Lazarus LH.

J Pharmacol Exp Ther. 2004 Apr;309(1):432-8. Epub 2004 Jan 12.

PMID:
14718580
41.

Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism.

Balboni G, Salvadori S, Guerrini R, Negri L, Giannini E, Bryant SD, Jinsmaa Y, Lazarus LH.

Bioorg Med Chem. 2003 Dec 1;11(24):5435-41.

PMID:
14642588
42.
43.

Unique high-affinity synthetic mu-opioid receptor agonists with central- and systemic-mediated analgesia.

Okada Y, Tsuda Y, Fujita Y, Yokoi T, Sasaki Y, Ambo A, Konishi R, Nagata M, Salvadori S, Jinsmaa Y, Bryant SD, Lazarus LH.

J Med Chem. 2003 Jul 17;46(15):3201-9.

PMID:
12852751
44.

Dmt and opioid peptides: a potent alliance.

Bryant SD, Jinsmaa Y, Salvadori S, Okada Y, Lazarus LH.

Biopolymers. 2003;71(2):86-102. Review.

PMID:
12767112
45.

Structural studies of [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond.

Okada Y, Fujita Y, Motoyama T, Tsuda Y, Yokoi T, Li T, Sasaki Y, Ambo A, Jinsmaa Y, Bryant SD, Lazarus LH.

Bioorg Med Chem. 2003 May 1;11(9):1983-94.

PMID:
12670649
46.

Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore.

Balboni G, Salvadori S, Guerrini R, Negri L, Giannini E, Jinsmaa Y, Bryant SD, Lazarus LH.

J Med Chem. 2002 Dec 5;45(25):5556-63.

PMID:
12459023
47.

Release of hemorphin-5 from human hemoglobin by pancreatic elastase.

Jinsmaa Y, Yoshikawa M.

Biosci Biotechnol Biochem. 2002 May;66(5):1130-2.

48.

Enterostatin (VPDPR) has anti-analgesic and anti-amnesic activities.

Takenaka Y, Nakamura F, Jinsmaa Y, Lipkowski AW, Yoshikawa M.

Biosci Biotechnol Biochem. 2001 Jan;65(1):236-8.

49.

Designing of an orally active complement C3a agonist peptide with anti-analgesic and anti-amnesic activity.

Jinsmaa Y, Takenaka Y, Yoshikawa M.

Peptides. 2001 Jan;22(1):25-32.

PMID:
11179594
50.

Retro-nociceptin methylester, a peptide with analgesic and memory-enhancing activity.

Jinsmaa Y, Takahashi M, Fukunaga H, Yoshikawa M.

Life Sci. 2000 Nov 10;67(25):3095-101.

PMID:
11125846

Supplemental Content

Loading ...
Support Center